Humacyte Inc
NASDAQ:HUMA

Watchlist Manager
Humacyte Inc Logo
Humacyte Inc
NASDAQ:HUMA
Watchlist
Price: 0.9605 USD -4.9% Market Closed
Market Cap: 179.9m USD
Section:
 

Relative Value

The Relative Value of one HUMA stock under the Base Case scenario is hidden USD. Compared to the current market price of 0.9605 USD, Humacyte Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HUMA Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

114.5
P/S
P/S
Price to Sales
114.5
vs History
58
vs Industry
11
Median 3Y
152.6
Median 5Y
317.9
Industry
7.9
Forward
59.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-6.5
Median 5Y
-7.9
Industry
23.7
Forward
-3.9
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-7.8
Median 5Y
-8.9
Industry
22
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-5.7
Median 5Y
-5.6
Industry
24.3
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
2
Median 3Y
7.3
Median 5Y
7.5
Industry
3.3
More Details
119.4
EV/S
EV/S
Enterprise Value to Sales
119.4
vs History
58
vs Industry
9
Median 3Y
157.5
Median 5Y
245.7
Industry
8.2
Forward
62.1
More Details
197.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
197.2
vs History
14
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.2
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-5.9
Median 5Y
-6.7
Industry
6.1
Forward
-3.1
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-5.4
Median 5Y
-6.7
Industry
6.5
Forward
-1.8
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-6.4
Median 5Y
-7.7
Industry
7.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-6.2
Median 5Y
-7.5
Industry
6.3
More Details
3
EV/IC
EV/IC
Enterprise Value to IC
3
vs History
82
vs Industry
33
Median 3Y
9.6
Median 5Y
9.8
Industry
5.7
More Details

Multiples Across Competitors

HUMA Competitors Multiples
Humacyte Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Humacyte Inc
NASDAQ:HUMA
179.9m USD 114.5 -4.9 -1.9 -1.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 770 229.5 -160 504.9 -194 904.1 -192 680.1
US
Abbvie Inc
NYSE:ABBV
403.8B USD 6.8 172 16.6 23.6
US
Amgen Inc
NASDAQ:AMGN
176.1B USD 4.9 25.1 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
152.4B USD 5.2 18.8 12.6 12.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.2B USD 9.8 31.3 23 24
US
Epizyme Inc
F:EPE
94.1B EUR 2 086.1 -532.3 -579.6 -564.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD 5.7 17.8 16.9 19.2
AU
CSL Ltd
ASX:CSL
83.6B AUD 3.6 18.6 12.6 15.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.4B USD 16.3 1 203 162.2 196.7
NL
argenx SE
XBRU:ARGX
43.8B EUR 14.3 33.6 57.9 59.5
P/S Multiple
Revenue Growth P/S to Growth
US
Humacyte Inc
NASDAQ:HUMA
Average P/S: 3 070 227
114.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 770 229.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 086.1
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.3
46%
0.4
NL
argenx SE
XBRU:ARGX
14.3
49%
0.3
P/E Multiple
Earnings Growth PEG
US
Humacyte Inc
NASDAQ:HUMA
Average P/E: 190
Negative Multiple: -4.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 504.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
172
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.8
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.3
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
10%
1.8
AU
CSL Ltd
ASX:CSL
18.6
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 203
N/A N/A
NL
argenx SE
XBRU:ARGX
33.6
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Humacyte Inc
NASDAQ:HUMA
Average EV/EBITDA: 40
Negative Multiple: -1.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 904.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.6
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
162.2
N/A N/A
NL
argenx SE
XBRU:ARGX
57.9
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Humacyte Inc
NASDAQ:HUMA
Average EV/EBIT: 46.2
Negative Multiple: -1.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 680.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.6
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.6
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.2
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
196.7
N/A N/A
NL
argenx SE
XBRU:ARGX
59.5
N/A N/A

See Also

Summary
HUMA intrinsic value, competitors valuation, and company profile.
DCF Valuation
HUMA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
HUMA stock valuation using valuation multiples.
Wall Street Estimates
HUMA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
HUMA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 306,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.